Zelira Therapeutics (ASX:ZLD) Interest Expense: A$-0.41 Mil (TTM As of Jun. 2025)


What is Zelira Therapeutics Interest Expense?

Zelira Therapeutics ASX:ZLD Interest Expense is A$-0.41 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zelira Therapeutics's interest expense for the six months ended in Jun. 2025 was A$ 0.44 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2025 was A$-0.41 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zelira Therapeutics's Operating Income for the six months ended in Jun. 2025 was A$ -2.17 Mil. Zelira Therapeutics's Interest Expense for the six months ended in Jun. 2025 was A$ 0.44 Mil. Zelira Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zelira Therapeutics  (ASX:ZLD) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zelira Therapeutics's Interest Expense for the six months ended in Jun. 2025 was A$0.44 Mil. Its Operating Income for the six months ended in Jun. 2025 was A$-2.17 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2025 was A$0.00 Mil.

Zelira Therapeutics's Interest Coverage for the quarter that ended in Jun. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Zelira Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Interest Expense Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.05 -0.08 -0.74 -0.41

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.21 -0.53 -0.85 0.44

Zelira Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of A$-0.41 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Interest Expense of A$-0.41 Mil as of Jun. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Interest Expense too high?
Zelira Therapeutics' current Interest Expense is A$-0.41 Mil.
How does Zelira Therapeutics' Interest Expense compare to MTNB and SXTP?
Zelira Therapeutics' Interest Expense of A$-0.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Interest Expense is A$-0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Interest Expense of A$-0.41 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Interest Expense is A$-0.41 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Interest Expense is A$-0.41 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.